<DOC>
	<DOC>NCT00347061</DOC>
	<brief_summary>Primary: To assess the safety of SL77.0499-10 10mg administered once daily for one year in patients with lower urinary tract symptoms related to BPH. Secondary: - To provide the information on the efficacy of SL77.0499-10 10mg administered once daily for one year in patients with lower urinary tract symptoms related to BPH. - To document the plasma concentration of SL77.0499-10 after repeated administration of SL77.0499-10 10mg administered once daily in patients with lower urinary tract symptoms related to BPH.</brief_summary>
	<brief_title>Long Term Safety of SL77.0499-10 (Alfuzosin) in Patients With BPH</brief_title>
	<detailed_description />
	<mesh_term>Hyperplasia</mesh_term>
	<mesh_term>Prostatic Hyperplasia</mesh_term>
	<mesh_term>Lower Urinary Tract Symptoms</mesh_term>
	<criteria>Having a symptomatic BPH diagnosed clinically by digital rectal examination and ultrasonography Suffering for at least 6 months from lower urinary tract symptoms related to BPH An IPSS total score ≥ 13 Out patient Patients previously treated with SL77.049910. Neurogenic bladder dysfunction, confirmed or suspected, irrespective of aetiology. Isolated bladder neck disease. Diagnosed carcinoma of the prostate. Previous prostatic surgery or other invasive procedures (thermotherapy…) for the treatment of BPH. Patients having an indwelling catheter. A residual urine &gt; 200mL. Patients with Moderate or sever hepatic insufficiency. Known hypersensitivity to alpha1blockers. Patients who have received antiandrogens, 5alphareductase inhibitors, LHRH analogues within the previous 3 months before Screening Patients judged inappropriate for admission to the study by the Investigator or the SubInvestigator.</criteria>
	<gender>Male</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2009</verification_date>
	<keyword>Benign Prostatic Hyperplasiam</keyword>
	<keyword>Adrenergic alpha-antagonist</keyword>
</DOC>